<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318744</url>
  </required_header>
  <id_info>
    <org_study_id>FirstPHShenyang</org_study_id>
    <nct_id>NCT03318744</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy for Silent Brain Infarction</brief_title>
  <acronym>ANTISBI</acronym>
  <official_title>Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First People's Hospital of Shenyang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First People's Hospital of Shenyang</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Silent brain infarction (SBI) or incidental infarct is common. Recent studies revealed
      individuals with SBI have an increased risk of future stroke. Even though the 2014 AHA/ASA
      recommendation for ischemic stroke and transient ischemic attack considered SBI as an entry
      point for secondary prevention, convincing evidence with regard to the preventive efficacy of
      antiplatelet therapy against incident stroke in SBI is scant. Investigators examine if
      antiplatelet therapy can effectively decrease the incidence of future stroke in SBI
      individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SBI is defined as a focal hyperintense lesion on T2-weighted images and/or fluid-attenuated
      inversion recovery with no corresponding symptoms in the clinical history of the patient that
      could be attributed to the lesion. SBI were distinguished from nonspecific subcortical and
      periventricular white matter lesions by the presence of a corresponding hypointense lesion on
      T1-weighted images.

      The prevalence of SBI varies from 5% to 62% in healthy population. To date, few studies
      investigate the association between SBI and ethnicity. The effectiveness of antithrombotics
      including aspirin against future symptomatic stroke in SBI patients remains to be
      established. Due to the high prevalence of ICAS among Chinese, and its nature of
      artery-to-artery microembolisms, investigators hypothesize that the prevalence of SBI among
      Chinese might be significantly higher than other races such as Caucasians and
      African-Americans.

      Recent study has revealed that SBI is associated with an 2-fold increase of future ischemic
      stroke. Yet, interventions such as antiplatelet therapies for reducing the stroke risk in SBI
      patients have not been investigated to our best knowledge. In this study, investigators
      examine whether regular oral aspirin can reduce the incidence of cerebrovascular events and
      mortality in SBI patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>composite outcome with any incident stroke, myocardial infarction and all-cause death</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke, intracranial cerebral hemorrhage, any bleeding, independence (mRS≥2)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3400</enrollment>
  <condition>Brain Infarction</condition>
  <arm_group>
    <arm_group_label>aspirin 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given aspirin 100mg once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given placebo oral tablets once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.</description>
    <arm_group_label>aspirin 100mg</arm_group_label>
    <other_name>Bayaspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo resembling aspirin tablet will be be given to participants in control arm.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cerebral infarction(s) identified by CT/MRI (≥ 3mm in diameter)

          -  absence of signs or symptoms of neurological dysfunction ascribed to the lesion(s)

          -  absence of PMH of neurological dysfunctions due to CNS lesion(s)

        Exclusion Criteria:

          -  Age under 45 years or above 80 years

          -  PMH of ICH within 180 days

          -  PMH of lobar hemorrhage of anytime

          -  Neuroimaging evidence suggesting cerebral microbleeds

          -  High risk of bleeding (e.g. recurrent gastrointestinal or genitourinary bleeding,
             active peptic ulcer disease)

          -  Anticipated requirement for long-term use (more than 28 days) of anticoagulants (e.g.
             recurrent deep vein thrombosis)

          -  Prior long-term use of anticoagulants (more than 28 days) or antiplatelet agents (more
             than 28 days)

          -  Prior retinal stroke/TIA (diagnosed either clinically or by imaging)

          -  Intolerance or contraindications to aspirin (including thrombocytopenia, prolonged
             INR)

          -  Prior ipsilateral carotid endarterectomy/stent

          -  Stenosis of culprit artery ≥ 70% (detected by ultrasound, MRA, CTA or DSA)

          -  Atrial fibrillation, or acute myocardial infarction, or acute congestive heart failure

          -  Impaired renal function: glomerular filtration rate&lt;60

          -  Mini Mental Status Examination score&lt;24 (adjusted for age and education)

          -  Medical contraindication to MRI

          -  Pregnancy or women of child-bearing potential who are not following an effective
             method of contraception

          -  Unable or unwilling to provide informed consent

          -  Unlikely to be compliant with therapy/unwilling to return for frequent clinic visits

          -  Patients concurrently participating in another study with an investigational drug or
             device

          -  Independence ascribed to limb deformity or prior disability

          -  Acute myocardial infarction

          -  Acute congestive heart failure

          -  Other anticipated reasons for future application of antiplatelet agents other than
             aspirin (eg. recent stenting, interventional surgeries, Lower-Extremity
             Atherosclerotic Arterial Disease etc)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Sui, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First People's Hospital of Shenyang</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Sui, MD PhD</last_name>
    <phone>+86 24 31956417</phone>
    <email>jakeyisui@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Xiao, MMed</last_name>
    <phone>+86 24 31956417</phone>
    <email>438505109@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shenyang Brain Hsopital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Sui, MD</last_name>
      <phone>+86 24 31956417</phone>
      <email>jakeyisui@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Ying Xiao, MMed</last_name>
      <email>438505109@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Sui, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bing Xu, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Zhou, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Li, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying Xiao, MD MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li Ren, MD MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yunxin Zhai, MD MMed</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xia Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xu Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Weber R, Weimar C, Wanke I, Möller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012 Feb;43(2):350-5. doi: 10.1161/STROKEAHA.111.631739. Epub 2012 Jan 19.</citation>
    <PMID>22267825</PMID>
  </reference>
  <reference>
    <citation>Chou CC, Lien LM, Chen WH, Wu MS, Lin SM, Chiu HC, Chiou HY, Bai CH. Adults with late stage 3 chronic kidney disease are at high risk for prevalent silent brain infarction: a population-based study. Stroke. 2011 Aug;42(8):2120-5. doi: 10.1161/STROKEAHA.110.597930. Epub 2011 Jun 23.</citation>
    <PMID>21700935</PMID>
  </reference>
  <reference>
    <citation>Nakagawa T, Sekizawa K, Nakajoh K, Tanji H, Arai H, Sasaki H. Silent cerebral infarction: a potential risk for pneumonia in the elderly. J Intern Med. 2000 Feb;247(2):255-9.</citation>
    <PMID>10692089</PMID>
  </reference>
  <reference>
    <citation>Wang Y, Zhao X, Liu L, Soo YO, Pu Y, Pan Y, Wang Y, Zou X, Leung TW, Cai Y, Bai Q, Wu Y, Wang C, Pan X, Luo B, Wong KS; CICAS Study Group. Prevalence and outcomes of symptomatic intracranial large artery stenoses and occlusions in China: the Chinese Intracranial Atherosclerosis (CICAS) Study. Stroke. 2014 Mar;45(3):663-9. doi: 10.1161/STROKEAHA.113.003508. Epub 2014 Jan 30.</citation>
    <PMID>24481975</PMID>
  </reference>
  <reference>
    <citation>Caplan LR, Hennerici M. Impaired clearance of emboli (washout) is an important link between hypoperfusion, embolism, and ischemic stroke. Arch Neurol. 1998 Nov;55(11):1475-82. Review.</citation>
    <PMID>9823834</PMID>
  </reference>
  <reference>
    <citation>Gupta A, Giambrone AE, Gialdini G, Finn C, Delgado D, Gutierrez J, Wright C, Beiser AS, Seshadri S, Pandya A, Kamel H. Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis. Stroke. 2016 Mar;47(3):719-25. doi: 10.1161/STROKEAHA.115.011889. Review.</citation>
    <PMID>26888534</PMID>
  </reference>
  <reference>
    <citation>Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Greenberg SM, Higashida RT, Kasner SE, Seshadri S; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Functional Genomics and Translational Biology; and Council on Hypertension. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017 Feb;48(2):e44-e71. doi: 10.1161/STR.0000000000000116. Epub 2016 Dec 15. Review.</citation>
    <PMID>27980126</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2017</study_first_submitted>
  <study_first_submitted_qc>October 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First People's Hospital of Shenyang</investigator_affiliation>
    <investigator_full_name>Dr. Yi Sui</investigator_full_name>
    <investigator_title>Director of Neurology</investigator_title>
  </responsible_party>
  <keyword>Silent Brain Infarction</keyword>
  <keyword>Antithrombotics</keyword>
  <keyword>Antiplatelet</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

